Literature DB >> 16901549

Phenotypic characterization of autoreactive T cells in multiple sclerosis.

Robert B Ratts1, Nitin J Karandikar, Rehana Z Hussain, Judy Choy, Sara C Northrop, Amy E Lovett-Racke, Michael K Racke.   

Abstract

MS has been hypothesized to result from autoreactive T cell responses against myelin antigens. In this report, we examined myelin-specific CD8 and CD4 T cells for two markers differentially expressed on naïve, memory and chronically stimulated T cells, CD28 and CD57. We observed differential expression on CD8 T cells in response to myelin antigens, but not in response to the recall antigen mumps. We demonstrate these cells display reduced proliferation and this may explain why therapies that limit the proliferation of T cells have had little effect on the course of MS, particularly later in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901549     DOI: 10.1016/j.jneuroim.2006.06.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

2.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

Review 3.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.

Authors:  Sushmita Sinha; Michael P Crawford; Sterling B Ortega; Nitin J Karandikar
Journal:  J Mult Scler (Foster City)       Date:  2015-01

5.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30

6.  Immune responses to mumps vaccine in adults who were vaccinated in childhood.

Authors:  Rima Hanna-Wakim; Linda L Yasukawa; Phillip Sung; Ann M Arvin; Hayley A Gans
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

Review 7.  Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Authors:  Rehana Z Hussain; Liat Hayardeny; Petra C Cravens; Felix Yarovinsky; Todd N Eagar; Benjamine Arellano; Krystin Deason; Cyd Castro-Rojas; Olaf Stüve
Journal:  J Neuroimmunol       Date:  2014-08-30       Impact factor: 3.478

8.  Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus.

Authors:  Maria T Cencioni; Roberta Magliozzi; Richard Nicholas; Rehiana Ali; Omar Malik; Richard Reynolds; Giovanna Borsellino; Luca Battistini; Paolo A Muraro
Journal:  Immunology       Date:  2017-09-21       Impact factor: 7.397

Review 9.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.